Holen Sie sich die Stockscreener-App
7.40
2.49%
0.18
Schlusskurs vom Vortag:
$7.22
Offen:
$7.17
24-Stunden-Volumen:
3.35M
Relative Volume:
1.04
Marktkapitalisierung:
$1.47B
Einnahmen:
$331.41M
Nettoeinkommen (Verlust:
$-226.54M
KGV:
-6.2712
EPS:
-1.18
Netto-Cashflow:
$-97.31M
1W Leistung:
+15.44%
1M Leistung:
-4.39%
6M Leistung:
-1.20%
1J Leistung:
+61.57%
1-Tages-Spanne:
$7.14
$7.51
1-Wochen-Bereich:
$6.33
$7.51
52-Wochen-Spanne:
$4.03
$9.50
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.40 | 1.47B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st
BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView
BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN
BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India
BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener
Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com
BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks
BioCryst appoints interim CFO following executive departure - Investing.com
BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India
BioCryst at Needham Conference: Growth Amidst Competition - Investing.com
(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan
BioCryst to Present at Upcoming Investor Conference - The Manila Times
BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan
Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.
Biocryst discovers new KLK5 inhibitors - BioWorld MedTech
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - news.stocktradersdaily.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):